Mighty Therapeutics

Mighty Therapeutics (formerly Stealth) is pioneering a new class of medicines that directly target mitochondrial dysfunction. Learn more at

[Mighty Therapeutics @Mighty_Tx]

We are pleased to share an update on our Phase 4 trial in Barth syndrome and upcoming presentations at the Biennial @BarthSyndrome Foundation International Scientific, Medical & Family Conference. Read the press release here: https://t.co/eOpJHPn9hv

[Mighty Therapeutics @Mighty_Tx]

We are excited for an action packed @UMDF #MitoMed conference this week in Orlando! Stop by our booth to learn more about our latest updates in #MitochondrialMedicine.

[Mighty Therapeutics @Mighty_Tx]

We are pleased to announce that Stealth BioTherapeutics has rebranded as Mighty Therapeutics!

Our new name reflects the strength of the patients and families who inspire our work, and our commitment to advancing mitochondrial medicine.

Learn more here: https://t.co/9tEGYwrXfB

[Mighty Therapeutics @Mighty_Tx]

We’ll be in attendance at @OrphanConf this week! Come check out the following sessions that members of the Stealth team will be participating in.
#WODC2026

[Mighty Therapeutics @Mighty_Tx]

Stealth will be participating at today’s @reaganudall meeting on Affecting the Aging Trajectory. We look forward to contributing to productive discussions on regulatory frameworks for therapies targeting aging biology. Learn more about today's session at: https://t.co/k6rpSHNDAq

[Mighty Therapeutics @Mighty_Tx]

We are pleased to announce presentations on our latest research in mitochondrial medicine at the upcoming #Euromit2026 congress! Read the full press release here: https://t.co/DbSkuKAsub

[Mighty Therapeutics @Mighty_Tx]

#ICYMI Stealth BioTherapeutics announced a commercial and pipeline update. Learn more in the press release: https://t.co/sAZqMrv3t6

[Mighty Therapeutics @Mighty_Tx]

Stealth BioTherapeutics is pleased to announce we will be presenting at the upcoming @ARVOinfo annual meeting! Learn more in the press release here: https://t.co/VXTESOLHG8 #MitochondrialMedicine

[Mighty Therapeutics @Mighty_Tx]

Stealth is extremely excited to announce the appointment of David A. Brown, Ph.D., as Chief Scientific Officer to help advance the company's pioneering work in mitochondrial medicine. Read the full press release here https://t.co/uJRE9YH8zo

[Mighty Therapeutics @Mighty_Tx]

Stealth BioTherapeutics is heading to #JPM2026! We look forward to sharing our latest advancements in mitochondrial medicine as well as discussing the regulatory trends shaping the future of drug development. See you in San Francisco!

[Mighty Therapeutics @Mighty_Tx]

Today, Stealth BioTherapeutics announced a commercial and research and development update. Learn more in our press release: https://t.co/dpc6IxNEt9

[Mighty Therapeutics @Mighty_Tx]

Happy holidays to our community, partners, and supporters. Your dedication, collaboration, and commitment continue to inspire us every day. Thank you for being part of an incredible year. Wishing you and your loved ones a joyful holiday season and a bright, healthy New Year! ❄️💙

[Mighty Therapeutics @Mighty_Tx]

Stealth BioTherapeutics announces the Mito Assist™ Patient Support Program and a partnership with AnovoRx Specialty Pharmacy. https://t.co/lLDPn2eKjb

[Mighty Therapeutics @Mighty_Tx]

On behalf of the #BarthSyndrome patient community, we are thrilled to share that the @FDA has approved our medicine as the first-ever treatment for this ultra-rare, life-threatening disease. #MitochondrialDisease #RareDisease https://t.co/d7XYXiQcIv

[Mighty Therapeutics @Mighty_Tx]

We're honored to be named one of the #XPRIZEHealthspan semifinalists! Tune into the awards livestream 5/12 at 6pm ET to learn more about the cool work @XPRIZE does & how this year’s award nominees are revolutionizing the way we think about human health. https://t.co/sxuqTXLrax

[Mighty Therapeutics @Mighty_Tx]

We're looking forward to attending @RWCRetina, where we'll share highlights from our clinical program in #dryAMD including the trial design of our P3 ReNEW and ReGAIN trials. CEO, Reenie McCarthy, will also be presenting at the Retina Unplugged session today at 9:50am ET!

[Mighty Therapeutics @Mighty_Tx]

Stealth BioTherapeutics announces upcoming data presentations at the 2025 @ARVOinfo Annual Meeting. #ARVO2025

Read the full press release for more details: https://t.co/SwIyBNiiad

[Mighty Therapeutics @Mighty_Tx]

Attending #WODC2025? Don’t miss this conversation with CEO Reenie McCarthy and a panel of experts as they dive into the future of rare disease drug development.

[Mighty Therapeutics @Mighty_Tx]

Barth Syndrome Awareness Day is celebrated around the world on 4/5 to bring together all members of this ultra-rare disease community! Stealth is proud to work with such a resilient group of individuals who continue to increase awareness of Barth syndrome.
https://t.co/x4BkfsGuCT

[Mighty Therapeutics @Mighty_Tx]

Are you attending @InformaConnect #RareDiseaseSummit? Check out CEO Reenie McCarthy’s talk this afternoon as she presents at the pioneering perspectives spotlight session. Learn more here: https://t.co/FRhkI0lv4I